Efficacy of Parenteral Amantadine Therapy in the Treatment of Multiple System Atrophy With Predominant Parkinsonism
Conclusions
Our preliminary data show that IV amantadine may be a safe and effective therapy in MSA-P. A double-blind placebo-controlled trial is needed to establish the true benefit of amantadine therapy. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review
Conclusions
Almost 50% of parkinsonian patients with psychotic symptoms found Pim to be a useful medication, which they continue to take. Reasons for intolerance varied and were thought to be unrelated to the drug. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial
Conclusions
These preliminary data suggest that CBM588 in combination with antidepressants is effective and well tolerated in the treatment of TRD. Further studies using a larger, double-blind, parallel-group design are warranted to confirm these findings. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Phagophobia Successfully Treated With Low-Dose Aripiprazole in an Adolescent: A Case Report
We describe a case of phagophobia in a 15-year-old girl who was treated successfully with low-dose aripiprazole as an augmentation therapy after she witnessed her father choking while eating chicken. To our knowledge, this is the first report showing that phagophobia was successfully treated with aripiprazole. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Recanalization of Chronic Occlusion of the Middle Cerebral Artery With Tissue Plasminogen Activator Treatment: A Case Report
Conclusions
At present, tPA is the only approved treatment for acute ischemic stroke, although it presents a limited time frame to avoid severe medication-related adverse effects. Our report suggests nonatherosclerotic chronic MCA occlusion as an alternative application of tPA therapy. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
De Novo Myoclonic Status Epilepticus After Benzodiazepine Withdrawal
We describe a 94-year-old woman with Alzheimer dementia and long use of mirtazapine 30 mg/d and alprazolam 1 mg/d who developed MSE approximately 24 hours after abrupt discontinuation of alprazolam. The patient was taking sulfamethoxazole/trimethoprim for urinary tract infection, diagnosed 2 weeks before admission. She had no history of seizures. Routine laboratory examinations were normal and head computed tomography showed no acute injuries. She received a loading dose of 1000 mg of intravenous valproate (VPA). Continuous electroencephalogram monitoring revealed very frequent generalized spikes and polyspikes in a marked...
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Successful Intrathecal Baclofen Therapy for Intractable Paroxysmal Sympathetic Hyperactivity in Patient with Pontine Hemorrhage: A case report
We report a case of a patient with intractable PSH after pontine hemorrhage who was treated with intrathecal baclofen (ITB). A 61-year-old man was diagnosed with pontine hemorrhage expanding to the bilateral midbrain. Beginning 2 weeks after onset, he developed paroxysmal hyperthermia, tachycardia, tachypnea, hypertension, and generalized dystonic movements. Several medications were administered to the patient, including fentanyl patch, dantrolene, gabapentin, and β blockers. Nevertheless, PSH episodes continued to occur more than twice per day. Seven months after onset, we performed a trial of ITB injection, which led to...
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Aripiprazole in a Patient of PLA2G6-Associated Neurodegeneration With Psychosis
This report presents a patient with PLA2G6-related dystonia-parkinsonism, who had neuropsychiatric symptoms preceding movement symptoms. Antipsychotic drug was prescribed, and he developed parkinsonism years later. Differential diagnosis between drug-induced parkinsonism and PLA2G6-related dystonia-parkinsonism could be challenging. PLA2G6 sequencing has to be considered facing a patient with adulthood parkinsonism, especially when it is associated with initial psychiatric symptoms. Our case highlights a common problem treating psychiatric symptoms in neurodegenerative diseases that lead to parkinsonism. The use of antipsy...
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients
Objectives
The aim of this study was to evaluate postmarketing fingolimod safety and effectiveness in a real-world clinical population.
Methods
This was a retrospective, single-center study with active multiple sclerosis patients treated with fingolimod with at least 12 months of follow-up. Demographic and clinical and imaging characteristics, including annualized relapse rate (ARR), Expanded Disability Status Score, previous treatment, adverse events, treatment duration, and reason for discontinuation, were analyzed.
Results
Sixty-three patients were included; 61.9% were females. Mean age and mean disease duration...
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study
Objective
The aim of this study was to evaluate the relationship between antiparkinsonian treatments, especially dopamine agonist (DAs) and the development of postural disorders in patients with Parkinson's disease (PD).
Methods
We performed an exploratory case-control study. Cases were PD patients with camptocormia, Pisa syndrome, or anterocollis. Control subjects were PD patients without postural disorders matched by sex and age. Demographic and clinical data including pharmacologic treatments history were collected retrospectively. Characteristics of cases and control subjects were compared using parametric and non...
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Sexual Dysfunctions Induced by Pregabalin
Conclusions
In this case series, SDs were noticed with PGB in 41.33% (n = 31) (men, 13 [50%]; women, 18 [36.73%]), which included erectile dysfunction (n = 16, 51.61%), anorgasmia (n = 10, 32.26%), and loss of libido (n = 11, 35.48%). Sexual dysfunctions occurred within weeks after the use of PGB and were not dose related. They occurred with low therapeutic PGB doses (50–100 mg/d). Discontinuation of PGB resulted in improvement of SDs within weeks. To conclude, SDs are not infrequent adverse effects of PGB therapy. Pregabalin can induce erectile dysfunction, loss of libido, and anorgasmia. Sexual dysfunctions induced b...
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Modafinil Reduces Parasympathetic Activity but Does Not Influence Autonomic Reactivity to Orthostatic Load in Narcolepsy Type 1
Conclusions
We conclude that long-term use of modafinil does not influence the cardiac autonomic reactivity to orthostatic load expressed by the HRV changes in supine-standing-supine test in narcolepsy type 1 patients, but the parasympathetic cardiac activity may be reduced in quiet supine position in patients with narcolepsy taking modafinil. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - July 1, 2018 Category: Neurology Tags: Original Articles Source Type: research
Restless Genital Syndrome Induced by Milnacipran
Conclusions
We discuss the relationship with restless legs syndrome and the difference from akathisia. It is highly possible MLN affected her RGS because she experienced RGS for the first time after the dose of MLN was increased. A limitation of this report is that we stopped MLN and administered gabapentin enacarbil immediately. We should join MLN to the list of compounds suspected of inducing RGS. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Trazodone and Parkinsonism: The Link Strengthens
Trazodone, the most sedating atypical antidepressant, is widely used as an off-label hypnotic especially in the elderly. Although generally considered safe, it can potentially inhibit midbrain dopaminergic neurotransmission leading to the emergence of extrapyramidal adverse effects. Two previous cases of trazodone-induced parkinsonism have been described after its prolonged use as an antidepressant; however, there is no published case of secondary parkinsonism caused by trazodone in a nondepressed person after its use as a hypnotic. Here, we present a case of rapid development of bradykinetic-rigid parkinsonism temporally ...
Source: Clinical Neuropharmacology - May 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
Treatment of Depression With Duloxetine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes
We report a case in which an adult patient with MELAS and comorbid major depressive disorder demonstrated excellent response to the selective serotonin-norepinephrine reuptake inhibitor medication duloxetine. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2018 Category: Neurology Tags: Case Reports Source Type: research
